Effects Of Memantine Combined With Rivastigmine Versus Rivastigmine On Activities Of Daily Living In Alzheimer's Disease

Objective: To evaluate the efficacy of memantine combined wi th rivastigmine initiated simultaneous versus rivastigmine mono therapy o n ADL(20 item version in China)in the mild-to-moderate stage of AD.Through different neuropsychological scale tese,to explore The best therap y treatment plan.Methods : Choose 122 newly diagnosed AD patients as the research object,who come from Sichuan province people's hospital of neurology medicine outpatient and/or hospitalization in January 2014-December 2015,and met inclusion criteria of Alzheimer's patients.122 el igible patients will be randomized into the rivastigmine mono therapy or memantine plus rivastigmine combination therapy arm respectively in a ra tio of 1:1.According to the contrast before and after treatment,the gender,occupation,education degree and the disease severity of two groups sho ud be fairly.a simple mental state scale(MMSE),daily life ability scale(ADL),Alzheimer's disease assessment scale-cognitive subscales(ADAS-cog),the Relevant Outcome Scale for Alzheimer's Disease(ROSA),Zarit caregiver burden scale(ZBI)were used to evaluated patients and their ca regiver at the 0th,12 th,24th week respectively.Analysis of two groups pati ents before and after treatment as well as the comparison between the tw o groups patients daily life ability to improve the situation;At the same time record the side effects and adverse reactions of the two groups patients.Results:1.Before the treatment,Comparing the baseline score of MM SE,ADL,ADAS-cog,ROSA,ZBI and the patients' age,duration,sex ratio of the two groups,there were no statistically significant difference(p>0.05).2.After treatment,the MMSE and ROSA scores of two groups of pa tients was increased,the ADL,ADAS-cog,ZBI scores are down before tr eatment.The MMSE,ADL,ADAS-cog,NPI,ZBI score of the two gro ups from baseline data at 24 weeks after treatment is improved significan tly,the difference has statistical significance(p < 0.05).3.After 6 months treatment(24 weeks),in group A,MMSE,ROSA score just group were lower than two drugs combination group,ADL,ADAS-cog,ZBI ratin g score were higher than in the combination therapy group,the improving score of each scale in the combination group was significantly superior to the simple medicine group,there were significant difference(p< 0.05).(There was no statistically significant difference except PADL,P > 0.05).Conclusion: Rivastigmine versus memantine combined with rivastigmi ne can improve the daily life ability,cognitive function,and reduce the caregiver burden of patients with mild-to-moderate AD.Two drug combi nation therapy with mild-to-moderate AD daily life ability improvement may be superior to use only rivastigmine.During the treatment of 24 we eks,combined treatment group's adverse reactions do not increase.Differen t neuropsychological scale to the diagnosis of Alzheimer's disease and the clinical curative effect have an auxiliary significance.